Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mindfulness-based therapy plus escitalopram for depression, anxiety, and sleep in women with breast cancer
IRCT20190317043079N3Phase 3Completed
- Sponsor
- Babol University of Medical Sciences
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of escitalopram in major depressive disorder (MDD), anxiety disorder and sleep disorder (2 arms), sponsored by Babol University of Medical Sciences. Primary endpoint: Reducing depression, anxiety and improving sleep. Started Jan 2023; status: completed.
02
Drugs
escitalopram
03
Conditions
major depressive disorder (MDD)anxiety disordersleep disorder
Beyond the preview
Go deeper on IRCT20190317043079N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190317043079N3.